Hydroxychloroquine and a low antiresorptive activity bisphosphonate conjugate prevent and reverse ovariectomy-induced bone loss in mice through dual antiresorptive and anabolic effects

Abstract

Osteoporosis remains incurable. The most widely used antiresorptive agents, bisphosphonates (BPs), also inhibit bone formation, while the anabolic agent, teriparatide, does not inhibit bone resorption, and thus they have limited efficacy in preventing osteoporotic fractures and cause some side effects. Thus, there is an unmet need to develop dual antiresorptive and anabolic agents to prevent and treat osteoporosis. Hydroxychloroquine (HCQ), which is used to treat rheumatoid arthritis, prevents the lysosomal degradation of TNF receptor-associated factor 3 (TRAF3), an NF-κB adaptor protein that limits bone resorption and maintains bone formation. We attempted to covalently link HCQ to a hydroxyalklyl BP (HABP) with anticipated low antiresorptive activity, to target delivery of HCQ to bone to test if this targeting increases its efficacy to prevent TRAF3 degradation in the bone microenvironment and thus reduce bone resorption and increase bone formation, while reducing its systemic side effects. Unexpectedly, HABP-HCQ was found to exist as a salt in aqueous solution, composed of a protonated HCQ cation and a deprotonated HABP anion. Nevertheless, it inhibited osteoclastogenesis, stimulated osteoblast differentiation, and increased TRAF3 protein levels in vitro. HABP-HCQ significantly inhibited both osteoclast formation and bone marrow fibrosis in mice given multiple daily PTH injections. In contrast, HCQ inhibited marrow fibrosis, but not osteoclast formation, while the HABP alone inhibited osteoclast formation, but not fibrosis, in the mice. HABP-HCQ, but not HCQ, prevented trabecular bone loss following ovariectomy in mice and, importantly, increased bone volume in ovariectomized mice with established bone loss because HABP-HCQ increased bone formation and decreased bone resorption parameters simultaneously. In contrast, HCQ increased bone formation, but did not decrease bone resorption parameters, while HABP also restored the bone lost in ovariectomized mice, but it inhibited parameters of both bone resorption and formation. Our findings suggest that the combination of HABP and HCQ could have dual antiresorptive and anabolic effects to prevent and treat osteoporosis.

References

[1] Looker AC, Melton LJ 3rd, Harris TB, Borrud LG, Shepherd JA. Prevalence and trends in low femur bone density among older US adults: NHANES 2005-2006 compared with NHANES III. J. Bone Miner. Res., 2010, 25: 64-71

[2] Baghdadi S et al. Mortality following proximal femoral fractures in elderly patients: a large retrospective cohort study of incidence and risk factors. BMC Musculoskelet Disord, 2023, 24

[3] Mashiba T et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J. Bone Miner. Res., 2000, 15: 613-620

[4] Eastell R et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J. Bone Miner. Res., 2011, 26: 530-537

[5] Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J. Clin. Endocrinol. Metab., 2000, 85: 231-236

[6] Khan AA et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J. Bone Miner. Res., 2015, 30: 3-23

[7] Cummings SR et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J. Bone Miner. Res, 2018, 33: 190-198

[8] Anastasilakis, A. D. et al. Denosumab discontinuation and the rebound phenomenon: a narrative review. J. Clin. Med. 10, 152 (2021).

[9] Ponnapakkam T, Katikaneni R, Sakon J, Stratford R, Gensure RC. Treating osteoporosis by targeting parathyroid hormone to bone. Drug Discov. Today, 2014, 19: 204-208

[10] Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a decade of experience. J. Bone Miner. Res., 2012, 27: 2419-2428

[11] Cosman F et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med., 2016, 375: 1532-1543

[12] Sleeman A, Clements JN. Abaloparatide: a new pharmacological option for osteoporosis. Am. J. Health Syst. Pharm., 2019, 76: 130-135

[13] Solling ASK, Harslof T, Langdahl B. Current status of bone-forming therapies for the management of osteoporosis. Drugs Aging, 2019, 36: 625-638

[14] Leder, B. Z., Tsai, J. N., Jiang, L. A. & Lee, H. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up. Bone 98, 54–58 (2017).

[15] Black DM et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med., 2003, 349: 1207-1215

[16] Finkelstein JS et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med., 2003, 349: 1216-1226

[17] Cosman F, Nieves JW, Dempster DW. Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J. Bone Miner. Res., 2017, 32: 198-202

[18] Chavassieux P et al. Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment. J. Bone Miner. Res., 2019, 34: 1597-1608

[19] Shoback, D. et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J. Clin. Endocrinol. Metab 105, (2020).

[20] Rogers MJ, Monkkonen J, Munoz MA. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone, 2020, 139: 115493

[21] van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun., 1999, 264: 108-111

[22] Tsoumpra MK et al. The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants. Bone, 2015, 81: 478-486

[23] Brown JP. Long-term treatment of postmenopausal osteoporosis. Endocrinol. Metab. (Seoul), 2021, 36: 544-552

[24] Dunford JE et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther., 2001, 296: 235-242

[25] Xing L et al. Targeting anti-cancer agents to bone using bisphosphonates. Bone, 2020, 138: 115492

[26] Sun S et al. Bisphosphonates for delivering drugs to bone. Br. J. Pharmacol., 2021, 178: 2008-2025

[27] Yao Z et al. RANKL cytokine enhances TNF-induced osteoclastogenesis independently of TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast precursors. J. Biol. Chem., 2017, 292: 10169-10179

[28] Yao Z, Xing L, Boyce BF. NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J. Clin. Invest., 2009, 119: 3024-3034

[29] Ni CZ et al. Molecular basis for CD40 signaling mediated by TRAF3. Proc. Natl. Acad. Sci. USA, 2000, 97: 10395-10399

[30] Li J et al. TGFbeta-induced degradation of TRAF3 in mesenchymal progenitor cells causes age-related osteoporosis. Nat. Commun., 2019, 10

[31] Xiu Y et al. Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. J. Clin. Invest., 2014, 124: 297-310

[32] Motten AG et al. Photophysical studies on antimalarial drugs. Photochem. Photobiol., 1999, 69: 282-287

[33] Costedoat-Chalumeau N et al. A critical review of the effects of hydroxychloroquine and chloroquine on the eye. Clin. Rev. Allergy Immunol., 2015, 49: 317-326

[34] Shen G, Liu X, Lei W, Duan R, Yao Z. Plumbagin is a NF-kappaB-inducing kinase inhibitor with dual anabolic and antiresorptive effects that prevents menopausal-related osteoporosis in mice. J. Biol. Chem., 2022, 298: 101767

[35] Yi X et al. TNF-polarized macrophages produce insulin-like 6 peptide to stimulate bone formation in rheumatoid arthritis in mice. J. Bone Miner. Res., 2021, 32: 2426-2439

[36] Silva BC, Bilezikian JP. Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr. Opin. Pharmacol., 2015, 22: 41-50

[37] Rosenbaum JT et al. American college of rheumatology, american academy of dermatology, rheumatologic dermatology society, and american academy of ophthalmology 2020 joint statement on hydroxychloroquine use with respect to retinal toxicity. Arthritis Rheumatol, 2021, 73: 908-911

[38] Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm., 2016, 7: 27-31

[39] Rogers MJ, Crockett JC, Coxon FP, Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone, 2011, 49: 34-41

[40] Jobke B, Milovanovic P, Amling M, Busse B. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients. Bone, 2014, 59: 37-43

[41] Coxon FP et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J. Bone Miner. Res., 2000, 15: 1467-1476

[42] Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr. Opin. Pharmacol., 2006, 6: 307-312

[43] Halasy-Nagy JM, Rodan GA, Reszka AA. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone, 2001, 29: 553-559

[44] Maruotti N, Corrado A, Neve A, Cantatore FP. Bisphosphonates: effects on osteoblast. Eur. J. Clin. Pharmacol., 2012, 68: 1013-1018

[45] Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N. Engl. J. Med., 2009, 360: 53-62

[46] Weivoda MM, Hohl RJ. Effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation. Endocrinology, 2011, 152: 3113-3122

[47] Ebetino FH et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone, 2011, 49: 20-33

[48] Ebetino FH et al. Bisphosphonates: the role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use. Bone, 2022, 156: 116289

[49] Murtha LA et al. The role of pathological aging in cardiac and pulmonary fibrosis. Aging Dis., 2019, 10: 419-428

[50] Wang Y, Wehling-Henricks M, Samengo G, Tidball JG. Increases of M2a macrophages and fibrosis in aging muscle are influenced by bone marrow aging and negatively regulated by muscle-derived nitric oxide. Aging Cell, 2015, 14: 678-688

[51] Makitie RE et al. Defective WNT signaling associates with bone marrow fibrosis-a cross-sectional cohort study in a family with WNT1 osteoporosis. Osteoporos Int., 2018, 29: 479-487

[52] Bouxsein ML et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res., 2010, 25: 1468-1486

[53] Dempster DW et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res., 2013, 28: 2-17

Funding

U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)(R01AG076731)

U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(R01AR043510)

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)